Checkpoint Therapeutics, Inc. (CKPT)
NASDAQ: CKPT · Real-Time Price · USD
4.090
+0.050 (1.24%)
Apr 24, 2025, 10:25 AM EDT - Market open
Checkpoint Therapeutics Revenue
In the year 2024, Checkpoint Therapeutics had annual revenue of $41.00K, down -60.19%.
Revenue (ttm)
$41.00K
Revenue Growth
-60.19%
P/S Ratio
8,253.79
Revenue / Employee
$1,708
Employees
24
Market Cap
342.59M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 41.00K | -62.00K | -60.19% |
Dec 31, 2023 | 103.00K | -89.00K | -46.35% |
Dec 31, 2022 | 192.00K | -76.00K | -28.36% |
Dec 31, 2021 | 268.00K | -801.00K | -74.93% |
Dec 31, 2020 | 1.07M | -639.00K | -37.41% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CKPT News
- 27 days ago - Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 5 weeks ago - CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT - Business Wire
- 6 weeks ago - Sun Pharma to Acquire Checkpoint Therapeutics - PRNewsWire
- 4 months ago - Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval - Seeking Alpha
- 4 months ago - Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewsWire
- 5 months ago - Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date - Seeking Alpha
- 5 months ago - Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 7 months ago - Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 - GlobeNewsWire